CoChat
Sign Up
Cited by 16,303Global Cancer Incidence and ScreeningCervical Cancer and HPV ResearchColorectal Cancer Screening and Detection

Cancer statistics, 2023

Open access
Siegel, Rebecca L., Miller, Kimberly D., Wagle, Nikita Sandeep, Jemal, Ahmedin·2023·CA: A Cancer Journal for Clinicians
DOI 10.3322/caac.21763
Open this paper in CoChat — free accountOpen PDF

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus‐associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3322/caac.21763

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Breast cancer is the second leading cause of cancer-related deaths among women, particularly in transitioning countries.

    “Moreover, it is the second leading cause of cancer-related deaths among women, particularly in transitioning countries [3, 4].”

    From Nanosensitizer-assisted sonodynamic therapy for breast cancer (2025) · cites this paper as [3]

    The “Expected number of cancer deaths” section lists lung, breast, and colorectal cancers, in that order, as causing the greatest numbers of cancer deaths among US women. That supports breast cancer’s second-place ranking in the United States, but the paper does not establish the claim for transitioning countries; its estimates concern the United States. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • After about 2 decades of declining incidence in the United States, a 3% per annum average increase in prostate cancer incidence (notably at later stages of diagnosis) was reported from 2014 to 2019, in parallel with the stabilization of prostate cancer mortality.

    “After about 2 decades of declining incidence in the United States, however, a 3% per annum average increase in incidence (notably at later stages of diagnosis) was reported from 2014 to 2019, in parallel with the stabilization of prostate cancer mortality.96”

    From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [96]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 105 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Murphy SL, Kochanek KD, Xu J, Heron M. Deaths: final data for 2012. Natl Vital Stat Rep. 2015;31(8):1-117.
  2. Sherer MV, Qiao EM, Kotha NV, Qian AS, Rose BS. Association between prostate-specific antigen screening and prostate cancer mortality among non-Hispanic Black and non-Hispanic White US veterans. JAMA Oncol. 2022;8(10):1471-1476. doi:10.1001/ jamaoncol.2022.297 · DOI
  3. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemi- plimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. Published online September 12, 2022. doi:10.1056/ NEJMoa2209831 · DOI

Cited by

Sorted by citations

Related

Authors
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A.
Affiliations
American Cancer Society (US)
Corresponding author
Siegel, Rebecca L.
ORCID
Venue
CA: A Cancer Journal for Clinicians
Publisher
Wiley
Published
2023-01
Volume
73
Issue
1
Pages
17-48
ISSN
  • 0007-9235 (ISSN-L)
  • 1542-4863
DOI
10.3322/caac.21763
OpenAlex
W4315754639
Cited by
16,303
References
105
Citations by year
2026: 1258 · 2025: 4055 · 2024: 7644 · 2023: 3324 · 2022: 8 · 2021: 2 · 2020: 1 · 2018: 1 · 2017: 2 · 2015: 1 · 2014: 1
FWCI
2009.43
Type
journal article
Language
en
Open access
Licence
Locations
  • CA A Cancer Journal for Clinicians (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
cancer incidence, cancer mortality, cancer incidence trends, cancer mortality trends, prostate cancer, lung cancer, breast cancer, endometrial cancer, liver cancer, melanoma, cervical cancer, HPV vaccine, COVID-19 pandemic, racial disparities in cancer mortality, leukemia, kidney cancer, United States
MeSH terms
Aged, Female, Humans, Lung Neoplasms, Male, Melanoma, Middle Aged, Neoplasms, Registries, United States, Incidence, Multiple Endocrine Neoplasia Type 1, Racial Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review